Twist Bioscience Corporation Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Twist Bioscience Corporation (TWST) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $0 for the 3-month period ending 2023-12-31, per its 10-Q filed 2024-02-02.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2024-02-02
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2023-12-31 was $0.00.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2022-09-30 was $0.00.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2022-06-30 was $0.00.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2022-03-31 was $0.00.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2023 was $3.71M, a 56.34% decline from fiscal 2022.
- Twist Bioscience Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2022 was $8.50M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-Q · filed 2024-02-02 | |||
| 2023-09-30 | $3.71M 10-K · filed 2023-11-21 | |||
| 2022-09-30 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $0.00 derived: sum of 2 quarters · filed 2023-06-05 | $0.00 derived: sum of 3 quarters · filed 2023-06-05 | $8.50M 10-K/A · filed 2023-06-05 |
| 2022-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | $0.00 derived: sum of 2 quarters · filed 2022-08-08 | $8.50M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-06 | $8.50M 10-Q · filed 2022-05-06 | ||
| 2021-12-31 | $8.50M 10-Q · filed 2022-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |